Related references
Note: Only part of the references are listed.The Black Hole: CAR T Cell Therapy in AML
Erden Atilla et al.
CANCERS (2023)
Biomarkers as targets for CAR-T/NK cell therapy in AML
Ruonan Shao et al.
BIOMARKER RESEARCH (2023)
Clinical Pharmacology and Determinants of Response to UCART19, an Allogeneic Anti-CD19 CAR-T Cell Product, in Adult B-cell Acute Lymphoblastic Leukemia
Sandra Dupouy et al.
CANCER RESEARCH COMMUNICATIONS (2022)
CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy
Semjon Willier et al.
BLOOD (2021)
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Yongxian Hu et al.
CLINICAL CANCER RESEARCH (2021)
A novel and efficient tandem CD19- and CD22-directed CAR for B-cell ALL
Samanta Romina Zanetti et al.
MOLECULAR THERAPY (2021)
How I treat acute myeloid leukemia in the era of new drugs
Courtney D. DiNardo et al.
BLOOD (2020)
Current challenges and emerging opportunities of CAR-T cell therapies
Teresa R. Abreu et al.
JOURNAL OF CONTROLLED RELEASE (2020)
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Sarwish Rafiq et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
'Off-the-shelf' allogeneic CAR T cells: development and challenges
S. Depil et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Sequential Infusion of Anti-CD22 and Anti-CD19 Chimeric Antigen Receptor T Cells for a Pediatric Ph-Like B-ALL Patient That Relapsed After CART-Cell and Haplo-HSCT Therapy: A Case Report and Review of Literature
Jingsheng Hua et al.
ONCOTARGETS AND THERAPY (2020)
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
Simon Loff et al.
MOLECULAR THERAPY-ONCOLYTICS (2020)
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Matteo Libero Baroni et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Decitabine-Mediated Epigenetic Reprograming Enhances Anti-leukemia Efficacy of CD123-Targeted Chimeric Antigen Receptor T-Cells
Liangshun You et al.
FRONTIERS IN IMMUNOLOGY (2020)
A Phase 1 Study of NKX101, an Allogeneic CAR Natural Killer (NK) Cell Therapy, in Subjects with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-Risk Myelodysplastic Syndrome (MDS)
Carlos Bachier et al.
BLOOD (2020)
First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
Dries Deeren et al.
BLOOD (2020)
Will CAR T cell therapy have a role in AML? Promises and pitfalls
Katherine D. Cummins et al.
SEMINARS IN HEMATOLOGY (2019)
Novel monoclonal antibody-based therapies for acute myeloid leukemia
Linde M. Morsink et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
The Intersection between Tumor Angiogenesis and Immune Suppression
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2019)
Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype
Tessa Gargett et al.
CYTOTHERAPY (2019)
CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies
Ugo Testa et al.
CANCERS (2019)
Results from the Completed Dose-Escalation of the Hematological Arm of the Phase I Think Study Evaluating Multiple Infusions of NKG2D-Based CAR T-Cells As Standalone Therapy in Relapse/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
David A. Sallman et al.
BLOOD (2019)
How close are we to CAR T-cell therapy for AML?
Saar Gill
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2019)
NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
Robin Parihar et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
Susanne H. Baumeister et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Donor-Derived CD123-Targeted CAR T Cell Serves as a RIC Regimen for Haploidentical Transplantation in a Patient With FUS-ERG plus AML
Sun Yao et al.
FRONTIERS IN ONCOLOGY (2019)
VISTA is highly expressed on MDSCs and mediates an inhibition of T cell response in patients with AML
Liru Wang et al.
ONCOIMMUNOLOGY (2018)
Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
Jodi J. Lipof et al.
CANCERS (2018)
Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients With Acute Myeloid Leukemia
Rebecca Levin-Epstein et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22
Haiying Qin et al.
MOLECULAR THERAPY-ONCOLYTICS (2018)
Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
Waseem Qasim et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
Marco Ruella et al.
CANCER DISCOVERY (2017)
tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
Dina Schneider et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
Sarah K. Tasian et al.
BLOOD (2017)
MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia
Athalia Rachel Pyzer et al.
BLOOD (2017)
Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells (vol 44, pg 380, 2016)
Omkar U. Kawalekar et al.
IMMUNITY (2016)
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)
Meenakshi Hegde et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Eugenia Zah et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Methylation of NKG2D ligands contributes to immune system evasion in acute myeloid leukemia
A. Baragano Raneros et al.
GENES AND IMMUNITY (2015)
A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy
Brian Philip et al.
BLOOD (2014)
Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Saar Gill et al.
BLOOD (2014)
Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo
I. Pizzitola et al.
LEUKEMIA (2014)
Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults
Mohamed L. Sorror et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia
Armen Mardiros et al.
BLOOD (2013)
Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor
Sarah Tettamanti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde et al.
MOLECULAR THERAPY (2013)
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Zakaria Grada et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2013)
Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma
Alessandra Soriani et al.
ONCOIMMUNOLOGY (2013)
Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy
Christian S. Hinrichs et al.
BLOOD (2011)
Dual Roles of Immune Cells and Their Factors in Cancer Development and Progression
Brian F. Zamarron et al.
INTERNATIONAL JOURNAL OF BIOLOGICAL SCIENCES (2011)
Long-Term Prognosis of Acute Myeloid Leukemia According to the New Genetic Risk Classification of the European LeukemiaNet Recommendations: Evaluation of the Proposed Reporting System
Christoph Roellig et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias
P Nowbakht et al.
BLOOD (2005)
Share Paper
